HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein-E-deficient mouse model.

Abstract
Aliskiren is a direct renin inhibitor developed to treat hypertension. Several clinical studies have suggested that aliskiren has beneficial effects on cardiovascular diseases beyond its antihypertensive effect. In the present study, we examined whether aliskiren limits the progression of AAA (abdominal aortic aneurysm), VH (ventricular hypertrophy) and atherosclerosis in an AngII (angiotensin II)-infused mouse model. ApoE-/- (apolipoprotein-E-deficient) mice were infused subcutaneously with AngII (1000 ng/kg of body weight per day; 4 weeks) to induce AAA and VH. At the completion of the AngII infusion, mice were randomly allocated to three groups to receive vehicle control, low-dose aliskiren (10 mg/kg of body weight per day) or high-dose aliskiren (50 mg/kg of body weight per day) for 4 weeks. Suprarenal aortic diameter assessed by ultrasound was significantly smaller in mice administered aliskiren at days 42 and 56. Aliskiren also significantly reduced the normalized heart weight, ventricular myocyte cell width and aortic arch atherosclerosis. Aliskiren lowered PRR (pro-renin receptor) expression and MAPK (mitogen-activated protein kinase) activity in the suprarenal aorta and heart. Aortic infiltration of T-lymphocytes and macrophages was reduced by aliskiren. In conclusion, aliskiren limits the progression of AAA, VH and atherosclerosis in an AngII-infused mouse model.
AuthorsSai-Wang Seto, Smriti M Krishna, Corey S Moran, David Liu, Jonathan Golledge
JournalClinical science (London, England : 1979) (Clin Sci (Lond)) Vol. 127 Issue 2 Pg. 123-34 (Jul 2014) ISSN: 1470-8736 [Electronic] England
PMID24476071 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Amides
  • Apolipoproteins E
  • Fumarates
  • Angiotensin II
  • aliskiren
Topics
  • Amides (pharmacology)
  • Angiotensin II (metabolism)
  • Animals
  • Aorta, Abdominal (drug effects, metabolism)
  • Aortic Aneurysm, Abdominal (drug therapy, metabolism)
  • Apolipoproteins E (deficiency, metabolism)
  • Atherosclerosis (drug therapy, metabolism)
  • Blood Pressure (drug effects)
  • Disease Models, Animal
  • Fumarates (pharmacology)
  • Hypertension (metabolism)
  • Hypertrophy (drug therapy, metabolism)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: